Skip to content
Developing Oral Therapeutics in Chronic Fatigue

Developing Oral Therapeutics in Chronic Fatigue

Learn more

Advancing towards clinical trials

Mitodicure is developing MDC002 to treat patients with ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) regardless of immunological or non-immunological origin.

Our Mission

Mitodicure is focused on developing oral therapeutics to address significant unmet medical needs in diseases with chronic fatigue.

Our lead clinical candidate, MDC002, is a novel molecule to treat patients with exertional intolerance and post-exertional malaise. We are pursuing a patient-focused approach to build a leading therapeutics company for post-acute infection syndromes and non-infectious chronic fatigue, with an initial focus on ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome).

A novel approach against Chronic fatigue Syndrome

Convenient oral application of MDC002 delivers drug to skeletal muscles and blood vessels. Mitochondrial dysfunction is treated and blood flow to muscle and brain improved.


To inquire about partnering with Mitodicure on an indication for its MDC002 program, or to collaborate on an external program, please contact us.